CB2 receptor ligands for the treatment of psychiatric disorders
The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
1. A method for treating vocal and/or motor tic behavior disorders comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a selective estrogen receptor modulator in a pharmaceutically acceptable carrier, wherein the selective estrogen receptor modulator is selected from the group consisting of raloxifene, bazedoxifene, lasofoxifene, tamoxifen, afimoxifene, arzoxifene, ormeloxifene, toremifene, ospemifene, and a combination thereof.
2. The method according to claim 1 , wherein the selective estrogen receptor modulator is raloxifene.
3. The method according to claim 1 , wherein the behavior disorder is Tourette syndrome.
4. The method according to claim 1 wherein the pharmaceutical composition is formulated in a dosage form selected from the group consisting of a solution, suspension, emulsion, powder, tablet, capsule, dragee, depot, granules, syrup, transdermal patch, spray, and suppository.
5. The method of claim 1 wherein the pharmaceutical composition is a solid dosage form.
6. The method of claim 5 wherein the solid dosage form is enteric-coated.
7. The method according to claim 1 wherein the pharmaceutical composition is formulated as an injectable solution and wherein the composition is administered as an intravenous injection, an intra-arterial injection, an intramuscular injection, an intradermal injection, an intraperitoneal injection, an intrathecal injection, a depot injection or a subcutaneous injection.
8. The method according to claim 1 wherein the pharmaceutical composition is formulated for oral, inhalation, transdermal, vaginal and or rectal administration routes.
9. The method of claim 1 wherein the therapeutically effective amount of the selective estrogen receptor modulator administered to the subject in need thereof ranges from about 0.4 mg/kg to about 10 mg/kg.
10. The method of claim 1 comprising administering an average daily dose of the selective estrogen receptor modulator ranging from about 5 mg to about 500 mg.
11. The method of claim 1 wherein the pharmaceutical composition comprising the therapeutically effective dose of the selective estrogen receptor modulator in a pharmaceutically effective carrier is administered to a human or non-human subject in need thereof once a week to 3 times per day.
12. A method for treating Tourette syndrome comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of raloxifene in a pharmaceutically acceptable carrier.